Resonance Specialties shareholders approved a final dividend of ₹1 per share and authorized related party transactions worth up to ₹40 crore during its 37th Annual General Meeting held on August 4, 2026. The virtual meeting, presided over by Chairman Raj Kamal Prasad Verma, also saw the re-appointment of Director Charchit Jain and Statutory Auditors Kailash Chand Jain & Co., signaling continuity in governance for the pharma ingredients manufacturer.

The Board of Directors proposed the dividend at 10% on the face value of ₹10 per equity share. This payout reflects the company’s commitment to returning capital to shareholders while maintaining operational stability. The approval process followed electronic voting conducted between July 31, 2026, and August 3, 2026, with July 28, 2026, as the cut-off date for determining voting entitlements. M/s Alok Khairwar & Associates served as the scrutinizer for the remote e-voting process under Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Resolutions Passed

Shareholders voted on several ordinary and special business items during the AGM. The key outcomes include:

The most significant special resolution concerned the approval for entering into related party transactions during any financial year not exceeding an aggregate amount of ₹40 crore with Kaygee Laboratories Private Limited. This cap provides the management with flexibility to execute necessary commercial agreements without seeking fresh shareholder approval for each transaction, provided the total does not breach the limit.

Governance and Compliance

The meeting adhered to strict regulatory compliance standards. Representatives from the Statutory Auditors, Secretarial Auditors, and the Scrutinizer were present via video conference. Chairman Raj Kamal Prasad Verma confirmed that the quorum was present throughout the session. He noted that there were no qualifications, adverse remarks, or observations in the Independent Auditors Report or the Secretarial Audit Report, indicating clean compliance for the period ended March 31, 2026.

The Whole-time Director addressed queries from members during the Q&A session before the e-voting module remained open for an additional 15 minutes for attendees who had not voted remotely. The meeting concluded at 1:20 p.m. Following the receipt of the scrutinizer’s report, the results were declared and posted on the company’s website and displayed at its registered office in Mumbai.

What the Numbers Show

The decision to declare a ₹1 per share dividend represents a modest return to equity holders, consistent with the company’s conservative capital allocation strategy. By capping related party transactions at ₹40 crore, the board has established a clear transparency boundary for dealings with Kaygee Laboratories Private Limited, ensuring that significant commercial ties remain subject to annual shareholder oversight rather than indefinite open-ended approvals.

Resonance Specialties Limited delivered a robust performance for the quarter ended June 30, 2026, reporting a sharp year-on-year surge in profitability alongside a significant strategic acquisition announcement. The Board of Directors, at their meeting held on August 4, 2026 in Mumbai, approved the unaudited financial results for Q1 and also greenlit the purchase of a manufacturing facility in Mandideep, Madhya Pradesh from a promoter group entity.

Strong Revenue and Profit Growth in Q1

The company's revenue from operations rose to ₹3,258.41 lakhs for the quarter ended June 30, 2026, compared to ₹2,127.42 lakhs in the corresponding quarter of the previous year. Total income, including other income of ₹53.78 lakhs, stood at ₹3,312.19 lakhs. Net profit for the quarter came in at ₹574.42 lakhs, a substantial jump from ₹163.04 lakhs reported in Q1 of the prior year. On a sequential basis, net profit also improved from ₹459.56 lakhs in the quarter ended March 31, 2026.

The following table summarises the key financial metrics across periods:

Expense Breakdown

Total expenses for Q1 stood at ₹2,547.26 lakhs, compared to ₹1,912.89 lakhs in the year-ago quarter. The key expense components for the quarter ended June 30, 2026 are detailed below:

• Cost of materials consumed: ₹1,360.36 lakhs
• Conversion charges: ₹332.13 lakhs
• Changes in inventories: ₹221.46 lakhs
• Employee benefits expense: ₹161.93 lakhs
• Other expenses: ₹436.29 lakhs
• Depreciation and amortisation: ₹33.82 lakhs
• Finance costs: ₹1.27 lakhs

Geographical Segment Performance

The company operates in a single primary business segment — Chemical Manufacturing — with a secondary geographical segmentation. International revenues saw a notable increase, as shown below:

Revenue from outside India more than doubled year-on-year to ₹2,326.08 lakhs from ₹1,065.49 lakhs, becoming the dominant contributor to total revenue in Q1.

Acquisition of Mandideep Manufacturing Facility

In a significant strategic development, the Board approved the purchase of a manufacturing facility located at Plot No. 6, New Industrial Area-II, Mandideep, Dist. Raisen - 462046, Madhya Pradesh from Kaygee Laboratories Private Limited (KLPL), a promoter group company. The key details of the proposed transaction are as follows:

The facility, originally set up in 1990, has been manufacturing and supplying chemical intermediates and certain APIs exclusively to Resonance Specialties on a job work basis. The unit has been recently inspected and approved by WHO, Geneva. The acquisition is intended to secure uninterrupted production, enhance operational control and efficiency, and eliminate costs associated with outsourcing manufacturing activities. The transaction is stated to be outside any scheme of arrangement and will not result in any change in the shareholding pattern of the company.

Kaygee Laboratories Private Limited holds 14.35% of the equity share capital of Makers Laboratories Limited, which in turn holds 45.48% of the equity share capital of Resonance Specialties. Additionally, Kaygee Investments Private Limited, another promoter group company, holds 8.77% of the equity share capital of the company.

Financial Position and Auditor's Review

As of March 31, 2026, the company's paid-up equity share capital stood at ₹1,154.40 lakhs (face value ₹10 per share), other equity at ₹5,802.75 lakhs, and net worth at ₹7,323.77 lakhs. The unaudited financial results for Q1 were reviewed by independent auditors Kailash Chand Jain & Co., Chartered Accountants (Firm Registration No.: 112318W), who noted no material misstatements. The results were prepared in accordance with Ind AS-34 and reviewed by the audit committee before Board approval. As of June 30, 2026, the company does not have any subsidiary, associate, or joint venture company.